Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
DYN filed a Rule 144 notice reporting a recent restricted‑stock issuance and a resale by an affiliate. The filing lists 4,062 Restricted Stock Units granted on 05/12/2026 and a reported resale of 5,727 shares on 04/01/2026 by Erick Lucera. The excerpt shows 165,313,796 shares outstanding as of 05/13/2026.
Dyne Therapeutics reported first quarter 2026 results and highlighted progress in its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. Cash, cash equivalents and marketable securities were $972.2 million as of March 31, 2026, which the company expects will fund operations into the first quarter of 2028.
For the quarter ended March 31, 2026, research and development expenses were $100.9 million versus $106.4 million a year earlier, while general and administrative expenses rose to $24.4 million from $15.9 million, mainly to prepare for a potential z-rostudirsen launch. Net loss was $120.9 million, or $0.73 per share, compared with a net loss of $115.4 million, or $1.05 per share, in the prior-year period.
Clinically, Dyne completed a positive pre-BLA meeting with the FDA for z-rostudirsen in exon 51 DMD, remains on track to submit a BLA for U.S. Accelerated Approval in Q2 2026, and is planning a potential U.S. launch in Q1 2027. The company also reached its target of 60 participants in the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, initiated the Phase 3 HARMONIA trial, and is planning data from the ACHIEVE cohort in Q1 2027 to support a potential BLA submission in early Q3 2027.
Dyne Therapeutics reported a net loss of $120.9 million for the quarter ended March 31, 2026, slightly higher than the $115.4 million loss a year earlier, as it continues to advance multiple neuromuscular programs.
Research and development expenses were $100.9 million, reflecting manufacturing and clinical work on z-rostudirsen for Duchenne muscular dystrophy and z-basivarsen for myotonic dystrophy type 1, plus preclinical efforts in FSHD and Pompe. General and administrative costs rose to $24.4 million as Dyne scales commercial and corporate infrastructure. The company ended the quarter with $972.2 million in cash, cash equivalents and marketable securities and a term loan balance of $150.0 million, and believes this liquidity will fund operations, debt service and capital needs into the first quarter of 2028 while it targets potential first product launches beginning in 2027.
Dyne Therapeutics, Inc. reported that investment entities associated with director Jason P. Rhodes sold a total of 106,723 shares of its common stock in open-market transactions. The sales occurred on May 4–6, 2026 at weighted average prices around $18.00–$18.18 per share under a Rule 10b5-1 trading plan.
The trades were executed by Atlas Venture-managed funds and related partnerships that hold Dyne shares indirectly for investors. After these transactions, the entities still hold multi-million-share positions in Dyne across several funds, while Rhodes disclaims beneficial ownership beyond any pecuniary interest.
FMR LLC reported beneficial ownership of 8,908,979.89 shares of Dyne Therapeutics common stock, representing 5.4% of the class as of 03/31/2026. The filing shows sole voting power of 8,900,472 shares and sole dispositive power of 8,908,979.89 shares, and references a 13d-1(k) agreement in Exhibit 99.